Merck announced Friday that updated data on its experimental COVID-19 pill show the drug is less effective than previously reported, and will now move to test treatment for safety.
Merck said the pill, Molnupiravir, showed a 30% reduction in hospitalization and deaths based on data from roughly 1,400 patients. Figures from an interim study released Oct. 1 showed an approximately 50% efficacy based on data from over 1,400 patients.
Read More